NasdaqGS:JAZZPharmaceuticals
Why Jazz Pharmaceuticals (JAZZ) Is Up 5.2% After Modeyso Receives FDA Approval for Rare Brain Cancer
In August 2025, Jazz Pharmaceuticals announced that the FDA granted accelerated approval for Modeyso™ (dordaviprone), the first and only approved treatment for H3 K27M-mutant diffuse midline glioma in adults and children with progressive disease after prior therapy.
This milestone introduces a new therapy option for an ultra-rare and aggressive brain cancer where effective treatments have historically been unavailable, highlighting Jazz’s commitment to addressing unmet medical needs in...